Cervical cancer
Conditions
Interventions
Experimental group:Kangfuxin liquid
Control group:None
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with cervical cancer first diagnosed by pathology; 2. Patients with stage IB-IV (2019 FIGO stage) requiring radiotherapy; 3. Aged 18-70 years; 4. Have not received pelvic radiotherapy before enrollment; 5. ECOG general condition score 0-2; 6. The expected survival period is more than 12 months; 7. Laboratory tests before radiotherapy and chemotherapy meet the following conditions: (1) Liver function: total bilirubin = 80 mL/min; (3) Blood function: absolute neutrophil count (ANC) >=2x10^9/L, platelet count >=100x10^9/L and hemoglobin >=9g/dL; 8. Agree and sign the informed consent form (if the patient himself has no judgment ability, his legal guardian is required to sign the informed consent form).
Exclusion criteria
Exclusion criteria: 1. History of rectal-related surgery in the past; 2. The tumor was found to have rectal invasion before treatment; 3. Patients who are pregnant or breastfeeding; 4. Those with recurrent proctitis before radiotherapy (more than 1 time/month); 5. Patients with Crohn's disease and ulcerative colitis; 6. At the same time receiving experimental treatments of other clinical studies (in the treatment period of clinical studies or participating in clinical trials of other drugs within 30 days); 7. Elderly patients with dry stomatitis; 8. Those with severe heart, lung, liver and kidney dysfunction, such as decompensated heart, lung, kidney, liver and other major organ dysfunction and failure, cannot tolerate radiotherapy; 9. Inability to take orally or absorb drugs through the digestive tract; 10. There are factors affecting administration, distribution, metabolism, excretion, etc., such as mental disorders, central nervous system disorders, chronic diarrhea, ascites, pleural effusion, etc.; 11. Long-term use of immunosuppressive agents or combined use of immunosuppressive agents after organ transplantation; 12. Those who have a history of other malignant tumors before enrollment and those who have a history of other malignant tumors at the same time; 13. Patients with cognitive impairment, or poor compliance with radiotherapy and chemotherapy as judged by the investigator; 14. Those who are deemed inappropriate by the investigator to conduct clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of stools; | — |
Countries
China
Contacts
Public ContactYang Xiaojing
Shanghai Sixth People's Hospital
Outcome results
None listed